GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (FRA:E08A) » Definitions » Institutional Ownership

Exagen (FRA:E08A) Institutional Ownership : 10.38% (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Exagen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Exagen's institutional ownership is 10.38%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Exagen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Exagen's Float Percentage Of Total Shares Outstanding is 66.98%.


Exagen Institutional Ownership Historical Data

The historical data trend for Exagen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Institutional Ownership Chart

Exagen Historical Data

The historical data trend for Exagen can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 14.23 13.25 11.22 11.21 11.08 11.08 11.08 10.45 10.39 10.38

Exagen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Exagen (FRA:E08A) Business Description

Traded in Other Exchanges
Address
1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Exagen (FRA:E08A) Headlines

No Headlines